Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily supplement help the body fight off HPV?

NCT ID NCT07697196

Disease control Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests whether a daily oral supplement containing green tea extract (EGCG), folic acid, vitamin B12, and hyaluronic acid can help women clear a persistent human papillomavirus (HPV) infection. HPV is a common virus that can cause cervical cancer if it stays in the body for a long time. The trial involves 42 women aged 25 and older who have had HPV for at least 9 months and have low-grade cervical changes. Half will take the supplement for six months, while the other half receive standard care. Researchers will measure whether the virus's activity in cells decreases, which could indicate the body is clearing the infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pervistop (epigallocatechin gallate, folic acid, vitamin B12, hyaluronic acid)
What this could lead to
If effective, this supplement could offer a simple, non-invasive way to help the body clear persistent HPV and reduce the risk of cervical cancer.
What could go wrong
This is a small early-stage trial with only 42 participants, so results may not apply broadly. Dietary supplements are not regulated as strictly as drugs, and the effect may be modest or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 42 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 25 years old 2. Positive HPV DNA test with genotyping 9-24 months prior to Day 0 3. Positive HPV DNA test with genotyping at Day 0 4. Presence of an HPV-related cervical lesion within 5-24 months prior to Day 0. This lesion will be defined alternatively as: 1. Pap test: LSIL, ASC-US. 2. Colposcopic impression suggestive of a low-grade lesion. 3. Histologic report of a colposcopic biopsy consistent with a low-grade lesion. 5. Previous HPV vaccination (latest dose at least 24 months earlier than Day 0) 6. Patients able to accept and sign informed consent for the study 7. Patients able to adhere to the proposed study protocol Exclusion Criteria: 1. High grade cervical lesions (HSIL) 2. Ongoing pregnancy, evaluated through a rapid chromatographic immunoassay for qualitative detection of hCG in urine 3. Ongoing breastfeeding 4. Primary or secondary immunodepression due to pharmacological treatments 5. No HPV vaccination 6. Daily assumption of other products containing green tea 7. Hypersensitivity or allergy to the substances contained in the supplement

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anogenital human papillomavirus infection cervical squamous intraepithelial neoplasia human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV disease HPV genital infection HPV infection HPV integration HPV persistence Low grade squamous intraepithelial lesions of the cervix

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS San Raffele Hospital

    Milan, Italy, 20100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.